Endeavor Pharmaceuticals

Endeavor BioMedicines is a clinical-stage precision medicine company focused on developing therapies for oncology and fibrosis. The company's lead candidate, ENV-101, is a small molecule inhibitor of the Hedgehog signaling pathway currently in Phase 2 trials for idiopathic pulmonary fibrosis (IPF). Endeavor's pipeline also includes ENV-201, a ULK1/2 inhibitor targeting autophagy in KRAS-mutant cancers, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate. By targeting the genetic drivers of disease and the mechanisms of resistance, Endeavor aims to provide transformative treatments for patients with high unmet medical needs.